The therapeutic community is abuzz with anticipation surrounding retatrutide, a new dual GIP and GLP-1 target that’s demonstrating significant promise in clinical trials for managing obesity. Unlike some available weight loss solutions, retatrutide appears to provide a significant substantial loss in body size and benefit metabolic function, part